Advances in the Treatment of Diffuse Large B Cell Lymphoma: ADCs, Bispecific Antibodies, CAR T Therapies and Combinations – Live

Description

Program Description

---

Click to Go to the Event Registration

Join us for a 90-minute live, virtual Zoom webinar on “Advances in Diffuse Large B-Cell Lymphoma Treatment”. This interactive session will feature didactic lectures from leading experts in the field, delving deep into the latest breakthroughs involving ADCs, bispecific antibodies, CAR T-cell therapies, and combination approaches. Don’t miss this opportunity to gain valuable insights and participate in a live Q&A session with the faculty. Register today to learn more about the future of DLBCL treatment!

DLBCL is the most common subtype of mature B-cell non-Hodgkin’s lymphoma (NHL). Gene expression profiling has identified distinct subtypes within DLBCL based on cell of origin (COO): germinal center B-cell (GCB) subtype and activated B-cell (ABC) subtype. GCB DLBCL is associated with an improved outcome compared with ABC DLBCL in patients treated with conventional chemoimmunotherapy with R-CHOP. The up-front treatment approach remains the same for both GCB and ABC subtypes. Accurate diagnosis of the DLBCL, appropriate patient selection, and effective management of the unique spectrum of adverse events associated with targeted therapies should be an integral part of managing patients with relapsed and refractory disease. Referral of appropriate patients for participation in well-designed prospective clinical trials should be considered to facilitate the development of novel chemotherapy-free treatment options.

Agenda

---

• Discuss the classification, molecular characterization, genetic subtypes, risk stratification, and upfront therapy of DLBCL
  Ken H. Young, MD, PhD
• Discuss novel therapies such as ADCs, CAR T, BsAbs, XPO1, combinations for relapsed and refractory DLBCL, and strategies to monitor adverse effects
  Fredrick B. Hagemeister, MD

Intended Audience

---

Hematologists/oncologists, nurse practitioners, physician assistants, and nurses involved in diagnosing and treating patients with diffuse large B-cell lymphoma (DLBCL)

Commercial Supporter

---

Supported by an educational grant from ADC THERAPUETICS AMERICA, INC.